2/24/2012

Defibrotide prophylaxis can reduce cases of hepatic veno-occlusive disease among patients younger than 18 undergoing hematopoietic stem cell transplantation, German researchers found. The study in The Lancet journal showed that 12% of patients who received the drug developed veno-occlusive disease 30 days after transplantation, compared with 20% in the control group.

Full Story:
DoctorsLounge.com

Related Summaries